Cantor Fitzgerald Remains a Buy on Aclaris Therapeutics Inc (ACRS)

By Carrie Williams

In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Aclaris Therapeutics Inc (ACRSResearch Report), with a price target of $50. The company’s shares closed yesterday at $6.83, close to its 52-week low of $5.04.

Chen commented:

“We expect upwards earnings revisions to levels not reflected in sell-side consensus expectations to drive shares higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $50.”

According to, Chen is a 4-star analyst with an average return of 11.3% and a 39.8% success rate. Chen covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Bausch Health Companies Inc, and Amneal Pharmaceuticals Inc.

Currently, the analyst consensus on Aclaris Therapeutics Inc is a Moderate Buy with an average price target of $50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $21.97 and a one-year low of $5.04. Currently, Aclaris Therapeutics Inc has an average volume of 505.5K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Dermatology Therapeutics and Contract Research segments.